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Background: It is well known that increased airflow limitation as measured by spirometry 
is associated with the risk of exacerbation in patients with COPD. The forced oscillation 
technique (FOT) is a noninvasive method used to assess respiratory impedance (resistance 
and reactance) with minimal patient cooperation required. The clinical utility of the FOT in 
assessing the risk of exacerbations of COPD is yet to be determined. We examined the rela-
tionship between respiratory impedance as measured by FOT and exacerbations in patients 
with COPD.
Materials and methods: Among 310 patients with COPD (Global Initiative for Chronic 
Obstructive Lung Disease stages I–IV) who presented at the outpatient clinic of the Showa 
University Hospital from September 2014 through January 2015, 119 were collected and 
assigned into 2 groups according to their history of exacerbation: exacerbators and nonexacer-
bators. Respiratory resistance components and respiratory reactance components, as measured 
by FOT, were compared between the two groups.
Results: Exacerbators were significantly older and had a higher white blood cell count than 
nonexacerbators. Resistance at 20 Hz, reactance at 5 Hz (X5), resonant frequency (Fres), and 
area of low reactance (ALX) differed significantly between the two groups. In addition, among 
patients with stage II COPD, there were significant differences in X5, Fres, and ALX between the 
two groups despite no significant differences in respiratory function as assessed by spirometry. 
Finally, receiver operating characteristic curve analysis revealed that the reactance components 
rather than the resistance components were associated with the risk of exacerbation.
Conclusion: There were significant differences in respiratory impedance between exacerbators 
and nonexacerbators in patients with moderate COPD. FOT is a promising tool for assessing 
future exacerbations in patients with COPD.
Keywords: forced oscillation technique, respiratory system resistance and reactance, 
spirometry
Introduction
It is increasingly recognized that exacerbation is a key event in COPD because of its 
significant negative impacts on patients’ quality of life and poor prognosis.1–3 It was 
reported that exacerbations are associated with accelerated lung function loss in 
patients with COPD, particularly those with mild disease.4 Many studies have reported 
that an increased frequency of exacerbation is associated with more severe airflow 
obstruction in patients with COPD.5,6 Bronchial wall thickness and total lung emphy-
sema percentage were associated with COPD exacerbation frequency.7 The clinical 
symptoms of cough and sputum are associated with the frequency of exacerbation.8,9 
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Among clinical parameters, a history of frequent exacerba-
tions in the previous year is the most important and inde-
pendent predictor of exacerbation in the following year.9 
Identification of risk factors for exacerbation of COPD is 
clinically important because it enables adequate precaution-
ary measures, such as pharmacologic therapy and vaccine, 
in patients predisposed to COPD exacerbation.
The forced oscillation technique (FOT) is a noninvasive 
procedure that measures lung mechanics using sinusoidal 
sound waves at two or three different frequencies simulta-
neously. FOT parameters of respiratory system resistance 
(Rrs) and respiratory system reactance (Xrs) were measured 
by the application of a sine wave of airflow to the mouth at 
the resonant frequency of the respiratory system according 
to the principle established by Fisher et al.10 Rrs components 
include the resistance at 5 Hz (R5), the resistance at 20 Hz 
(R20), and the difference between R5 and R20 (R5−R20). 
Xrs components include the reactance at 5 Hz (X5), the 
differences between inspiratory and expiratory Xrs (ΔXrs), 
the resonant frequency (Fres), and the area of low reactance 
(ALX). FOT represents an alternative modality to conven-
tional pulmonary function tests because of its sensitivity in 
detecting peripheral airway obstruction. In addition, it can be 
performed independent of the patient’s efforts with minimal 
need for their cooperation.11,12 Therefore, FOT can be used 
in elderly patients and those with physical and cognitive 
limitations, and it would be helpful for these patients if FOT 
can detect exacerbations of COPD.
The utility of FOT has been reported most frequently in 
relation to asthma and COPD. Respiratory impedance (Rrs 
and Xrs) in patients with COPD is generally correlated with 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) staging, classified according to the degree of airway 
obstruction.13 Moreover, FOT can detect the pharmacologic 
effects of bronchodilators on small airways in patients with 
COPD despite an absence of change in forced expiratory 
volume in 1 second (FEV
1
).14 ΔXrs, particularly ΔX5, can be 
used for discrimination between COPD and asthma15,16 or for 
detection of expiratory flow limitation (EFL) that indicates 
dynamic hyperinflation in COPD.17,18 In a previous study, it 
was reported that increased Rrs is associated with frequent 
exacerbations in severe asthma.19 However, the association 
between respiratory impedance and exacerbations in patients 
with COPD has not been determined.
We hypothesized that respiratory impedance as assessed 
by FOT is associated with the increased risk of exacerbations 
independently from respiratory parameters as measured by 
conventional spirometry in patients with COPD. To prove 
this hypothesis, we evaluated the relationship between 
respiratory impedance as measured by FOT and the risk of 
exacerbation in patients with COPD.
Materials and methods
subjects and study design
This was a single-centered, retrospective case–control study. 
The analysis was based on data obtained from 310 patients 
with COPD (defined by GOLD) who presented at Showa 
University Hospital (Tokyo, Japan) from September 2014 
through January 2015. All patients were confirmed that 
their FEV
1
/forced vital capacity ratio (FEV
1
/FVC) ,0.7. 
As shown in Figure 1, we excluded some of the patients for 
the following reasons: 142 patients concurrently had chronic 
respiratory disease, 4 patients were receiving regularly oral 
corticosteroid therapy, and 45 patients did not undergo respi-
ratory function testing. The remaining 119 patients fulfilled 
our study criteria and were assigned into 2 groups: patients 
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?????????????????????????????????????????? ?????????????????????????????????????????????
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Figure 1 Flow chart of patient enrolment.
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who had one or more exacerbations within the past 2 years 
from the last visit (Exacerbators) and patients who had no 
exacerbations within the past 2 years from the last visit 
(Nonexacerbators). We defined an exacerbation as an acute 
event that fulfilled the following criteria:20 1) clinically sig-
nificant change in baseline dyspnea, cough, and/or sputum, 
2) presentation at the emergency department because of a 
need to receive oral corticosteroids or systemic corticosteroid 
therapy.
We collected data including exacerbations, age, gender, 
height, body weight, smoking history, blood counts, medi-
cal history, and respiratory function from the 119 patients. 
The white blood cell (WBC) count, absolute eosinophil 
count, and relative eosinophil count were determined within 
5 months before enrollment. The blood counts measured 
when the patients had infectious diseases were excluded. 
FOT and spirometry were also performed when the patients 
were free from infectious diseases and exacerbations for at 
least 2 months.
The study was performed in accordance with the prin-
ciples of the Declaration of Helsinki. The protocol was 
approved by the ethics committee of Showa University 
School of Medicine on March 25, 2016 (No 2029), and all 
subjects gave their written informed consent.
FOT
Rrs and Xrs were assessed by FOT (Mostgraph-01, Chest 
MI, Inc., Tokyo, Japan) in all subjects. All FOT assessments 
were performed by skilled clinical laboratory technicians. 
FOT was performed before spirometry in all patients to avoid 
bronchospasm caused by forceful expiration and inspiration. 
The subjects were requested to sit down, slightly stretch 
their neck, wear a nose clip, and put a mouthpiece into their 
mouth, without leaving any space between the lips and the 
mouthpiece. During impedance measurements, all subjects 
held their cheeks firmly with their hands. The measurement 
was conducted three times in a row, and the best data were 
adopted. We accepted resting ventilation with a coherence of 
0.7 or higher and excluded the value when resting ventilation 
was unstable with patients’ coughing, swallowing, phonation, 
or breath holding.11
spirometry
Respiratory function was assessed with the use of a spirom-
eter (CHESTAC-8900, Chest MI, Inc., Tokyo, Japan) in all 
subjects. The forced expiration maneuver was conducted 
with the subject in a standing position. Measurements were 
obtained in accordance with the guidelines for pulmonary 
function tests issued by the Japanese Respiratory Society.
% predicted FVC and % predicted FEV
1
 were calculated 
with new prediction equations of FVC and FEV
1
 provided by 
the Japanese Respiratory Society in 2001.21 Each equation is 
shown in the following:
 
Male:  predicted FVC (L) = 0.045* height (cm) - 
0.023* age - 2.258, predicted FEV
1
 (L) = 
0.036* height (cm) - 0.028* age - 1.178
 
Female:  predicted FVC (L) = 0.032* height (cm) - 0.018* 
age - 1.178, predicted FEV
1
 (L) = 0.022* height 
(cm) - 0.022* age - 0.005
statistical analyses
We performed all statistical analyses using JMP version 12 
software (SAS Institute Inc., Cary, NC, USA). The statisti-
cal significance of differences in the continuous variables 
between the Exacerbators and Nonexacerbators was assessed 
according to standard statistical criteria with the use of the 
Wilcoxon rank sum test or Kruskal–Wallis test, and the dif-
ferences in the categorical variables were analyzed using the 
Pearson χ2 test. The analyses of FOT parameters are adjusted 
for age, gender, height, and smoking status. To study the 
sensitivity and specificity of different parameters for the 
detection of exacerbations, receiver operating characteristic 
(ROC) curves were analyzed. The results are presented as 
numbers, percentages, and median (interquartile range). 
Two-sided P-values of ,0.05 were considered to indicate 
statistical significance.
Results
Patients
We studied 119 patients who fulfilled the study criteria. 
The characteristics of the study patients are summarized in 
Table 1. The patients’ median age was 73.0 (67.0, 79.0) years, 
and 106 (89%) of them were men. Among the 119 patients, 
37 (31.1%) were in Exacerbators and 82 (68.9%) were in 
Nonexacerbators (Figure 1). Exacerbators were significantly 
older (76.0 [71.0, 82.0] vs 72.5 [66.0, 79.0], P=0.029) and 
had a higher WBC count (6,900.0 [5,700.0, 8,800.0] vs 
6,150.0 [5,100.0, 7,000.0], P=0.013) than Nonexacerba-
tors. The proportion of patients receiving triple therapy was 
significantly higher in Exacerbators than in Nonexacerbators 
(27% vs 12%, P=0.045).
Among the 119 patients, 35 (29.4%) were classified as 
GOLD stage I, 47 (39.5%) were as GOLD stage II, and 37 
(31.1%) were as GOLD stages III and IV. Comparisons of 
clinical characteristics between Exacerbators and Nonexac-
erbators according to the subgroups are shown in Table 2. 
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Among patients with stage II, the proportions of patients 
receiving inhaled corticosteroids (35% vs 10%, P=0.034) 
and triple therapy (29% vs 0%, P=0.002) were significantly 
higher in Exacerbators than in Nonexacerbators. In addition, 
among patients with stage III and IV, Exacerbators’ history 
indicated more pack-years of smoking than Nonexacerbators 
(80.0 [50.0, 129.0] vs 53.0 [36.8, 84.8], P=0.013). There were 
no other significant differences in other variables or outcomes 
between Exacerbators and Nonexacerbators in patients with 
stage I, stage II, and III and IV.
spirometry and FOT measurements
Comparisons of spirometry data and FOT parameters 
between the three groups classified by severity are shown in 
Table S1. There were significant differences in all parameters 
obtained by spirometry and FOT between the groups. Table 3 
shows the comparison of the parameters obtained by spirom-
etry and FOT between Exacerbators and Nonexacerbators. 
Exacerbators had significantly lower % predicted FVC (85.8 
[73.8, 97.1] vs 99.2 [86.8, 109.7], P=0.049), % predicted 
FEV
1
 (58.1 [37.3, 70.0] vs 67.7 [48.2, 87.6], P=0.008), and 
FEV
1
/FVC (44.9 [37.6, 62.2] vs 56.3 [42.0, 69.5], P=0.006) 
than Nonexacerbators. Rrs and Xrs were measured by whole-
breath analysis with the use of FOT and compared between 
Exacerbators and Nonexacerbators. Regarding Rrs param-
eters, we found significant differences in R20 (2.88 [2.33, 
3.50] vs 2.39 [1.95, 3.02], P=0.028) between Exacerbators 
and Nonexacerbators. There were also significant differences 
in the Xrs parameters: X5 (-2.18 [-3.21, -0.94] vs -0.69 
[-2.12, -0.30], P=0.024), Fres (15.60 [10.72, 18.96] vs 9.50 
[6.82, 15.59], P=0.004), and ALX (15.99 [4.20, 27.83] vs 
3.58 [1.19, 16.61], P=0.008) between the two groups. Mean-
while, there were no significant differences in R5−R20 and 
ΔX5 between the two groups. We also compared Rrs and Xrs 
between the two groups by subgroup of disease severity, and 
the results are shown in Table 4. We found that among patients 
with stage II COPD, there were significant differences in X5 
(-1.33 [-3.21, -0.76] vs -0.73 [-1.30, -0.35], P=0.017), 
Fres (13.59 [9.83, 16.76] vs 9.44 [6.82, 12.02], P=0.042), 
and ALX (7.29 [3.36, 22.66] vs 2.94 [1.21, 6.87], P=0.021) 
between the two groups despite no significant differences 
in parameters measured with the use of spirometry.
Table 1 Characteristics of the 119 patients with COPD and comparison of characteristics between exacerbators and nonexacerbators
Characteristics All (n=119) Exacerbators (n=37) Nonexacerbators (n=82) P-value
Male, n (%) 106 (89) 33 (89) 73 (89) 0.979
age, years 73.0 (67.0, 79.0) 76.0 (71.0, 82.0) 72.5 (66.0, 79.0) 0.029*
smoking, pack per year 54.0 (30.0, 86.0) 55.0 (36.9, 106.5) 51.3 (29.3, 82.5) 0.178
smoking, never/former/current, n 4/83/32 1/30/6 3/53/26 0.189
BMI, kg/m2 22.3 (20.1, 24.7) 22.4 (20.1, 25.1) 22.3 (20.1, 25.1) 0.774
WBC count, /μl 6,300.1 (5,400.1, 7,300.1) 6,900.0 (5,700.0, 8,800.0) 6,150.0 (5,100.0, 7,000.0) 0.013*
eosinophil count, /μl 207.3 (131.3, 324.8) 188.4 (131.9, 281.1) 217.7 (131.3, 331.0) 0.618
% eosinophil, % 3.3 (1.9, 5.2) 3.0 (1.7, 4.6) 3.6 (2.5, 6.5) 0.231
Types of inhaled medication, n (%)
laBa 62 (52) 24 (65) 38 (46) 0.061
laMa 95 (80) 32 (86) 63 (77) 0.224
ICs 27 (23) 11 (30) 16 (20) 0.218
number of medications, n (%)
1 58 (49) 13 (35) 45 (55) 0.046*
2 31 (26) 12 (32) 19 (23) 0.287
3 20 (17) 10 (27) 10 (12) 0.045*
Details of medications (%)
laBa 11 (9) 3 (8) 8 (10) 0.774
laMa 47 (39) 10 (27) 37 (45) 0.062
ICs 0 (0) 0 (0) 0 (0) –
laBa/ICs 5 (4) 0 (0) 5 (6) 0.125
laMa/ICs 2 (2) 1 (3) 1 (1) 0.560
laBa/laMa 26 (22) 11 (30) 15 (18) 0.162
laBa/laMa/ICs 20 (17) 10 (27) 10 (12) 0.045*
no inhaled drug 8 (7) 2 (5) 6 (7) 0.700
Notes: all values are median (interquartile range) unless otherwise stated. exacerbator group consisted of patients experiencing one or more exacerbations within 2 years. 
nonexacerbator group consisted of patients who had never experienced exacerbation within 2 years. P-values represent statistical analyses between exacerbator and 
nonexacerbator groups. *P,0.05.
Abbreviations: BMI, body mass index; ICs, inhaled corticosteroids; laBa, long-acting beta-agonists; laMa, long-acting muscarinic antagonist; WBC, white blood cell.
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Predictive values of FOT parameters
Finally, we performed an ROC curve analysis for spirom-
etry data and FOT parameters to identify exacerbations in 
all 119 patients with COPD (Figure 2). % predicted FVC, 
% predicted FEV
1
, and FEV
1
/FVC yielded high area under 
the curve (AUC) values of 0.66, 0.65, and 0.61, respectively. 
Also, X5, Fres, and ALX yielded high AUC values of 0.70, 
0.69, and 0.68, respectively, indicating that Xrs is more 
closely associated with future exacerbations than Rrs. The 
accuracy of spirometry data and FOT parameters is shown 
in Table 5. The most closely associated parameter with 
exacerbations was X5, for which the optimum cutoff point 
was -0.875 kPa⋅L-1⋅s-1 with 81.1% sensitivity and 59.8% 
specificity. The optimum cutoff points for % predicted 
FVC, % predicted FEV
1
, FEV
1
/FVC, Fres, and ALX were 
94.7%, 81.1%, 50.5%, 13.585 Hz, and 4.03 kPa⋅L-1⋅s-1, 
respectively.
Discussion
Exacerbation is a key event in COPD because it accelerates 
lung function loss and decreases patients’ quality of life.1–3 The 
present study showed the differences in respiratory impedance 
between Exacerbators and Nonexacerbators in patients with 
COPD as measured by FOT. The values of R20, Fres, and 
ALX were higher in Exacerbators than in Nonexacerbators, 
while that of X5 was lower. To our knowledge, this is the first 
study to demonstrate differences in FOT parameters between 
Exacerbators and Nonexacerbators in patients with COPD.
The frequency of COPD exacerbation generally depends 
on the disease severity, classified as airflow limitation 
measured by the use of conventional spirometry. In the 
present study, lower pulmonary function as assessed by 
FVC and FEV
1
, older age, and higher WBC count were 
associated with exacerbations in patients with COPD. In 
line with our results, the ECLIPSE study demonstrated that 
disease severity and an elevated WBC count were associated 
exacerbations in patients with COPD; in addition, prior exac-
erbations, a history of gastroesophageal reflux, symptoms of 
heartburn, and a poorer quality of life were also found to be 
determinants of exacerbations.22 In particular, a history of 
exacerbations in the preceding year was the best determinant 
of exacerbations. In the present study, we demonstrated the 
possibility of FOT as a novel and objective indicator for the 
detection of exacerbation in COPD, representing a viable 
alternative to spirometry. Intriguingly, Gonem et al reported 
that, in patients with severe asthma, airway constriction as 
measured by FOT was associated with an exacerbation-prone 
phenotype.19
Recently, the importance of identifying patients with mild 
airway obstruction, such as those classified as GOLD stages I 
and II, has been recognized because of potential future 
impairment of their health status.23 In addition, the Genetic 
Epidemiology of COPD study introduced novel evidence that 
exacerbations accelerate lung function loss in patients with 
COPD, particularly in those with mild disease.3 Our study 
showed that among the subgroup of patients with stage II 
COPD, there were significant differences in FOT parameters 
between Exacerbators and Nonexacerbators despite no 
significant difference in respiratory function as measured 
by spirometry. This indicates that FOT can discriminate an 
Table 3 Comparisons of parameters measured by spirometry and FOT between exacerbators and nonexacerbators
Parameters All (n=119) Exacerbators (n=37) Nonexacerbators (n=82) P-value
spirometry
% predicted FVC 95.5 (81.7, 109.0) 85.8 (73.8, 97.1) 99.2 (86.8, 109.7) 0.049*
% predicted FeV1 64.5 (44.6, 80.8) 58.1 (37.3, 70.0) 67.7 (48.2, 87.6) 0.008*
FeV1/FVC, % 55.0 (41.7, 66.5) 44.9 (37.6, 62.2) 56.3 (42.0, 69.5) 0.006*
FOT/resistance (r)
r5, kPa⋅l-1⋅s-1 3.48 (2.77, 4.44) 3.96 (3.00, 4.79) 3.41 (2.59, 4.16) 0.349
r20, kPa⋅l-1⋅s-1 2.58 (2.02, 3.17) 2.88 (2.33, 3.50) 2.39 (1.95, 3.02) 0.028*
r5–r20, kPa⋅l-1⋅s-1 0.90 (0.49, 1.30) 1.16 (0.51, 1.57) 0.77 (0.49, 1.25) 0.821
FOT/reactance (X) 
X5, kPa⋅l-1⋅s-1 -0.96 (-2.58, -0.37) -2.18 (-3.21, -0.94) -0.69 (-2.12, -0.30) 0.024*
Fres, hz 11.2 (7.61, 17.0) 15.60 (10.72, 18.96) 9.50 (6.82, 15.59) 0.004*
alX, kPa⋅l-1 4.72 (1.41, 20.18) 15.99 (4.20, 27.83) 3.58 (1.19, 16.61) 0.008*
ΔX5, kPa⋅l-1⋅s-1 -0.34 (-1.71, 0.16) -1.08 (-2.12, 0.11) -0.06 (-1.10, -0.17) 0.520
Notes: all values are median (interquartile range). exacerbator group consisted of patients experiencing one or more exacerbations within 2 years. nonexacerbator group 
consisted of patients who had never experienced exacerbation within 2 years. P-values represent statistical analyses between exacerbator and nonexacerbator groups. The 
analyses of FOT parameters are adjusted for age, gender, height, and smoking status. *P,0.05.
Abbreviations: FOT, forced oscillation technique; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; r5, resistance at 5 hz; r20, resistance at 
20 hz; r5–r20, difference between r5 and r20; X5, reactance at 5 hz; Fres, resonant frequency; alX, reactance area; ΔX5, difference between inspiratory and expiratory 
respiratory system reactance.
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exacerbation-prone phenotype among patients with the same 
grade of mild severity. We believe that this is the key findings 
of our study. FOT has been reported to be more sensitive than 
spirometry in detecting COPD and in assessing the effects 
of bronchodilators.24,25 However, our findings do indicate the 
utility of FOT but do not necessarily confirm its superiority 
over conventional spirometry in assessing exacerbation in 
patients with COPD.
Dellacà et al reported that ΔXrs can be used to detect the 
presence of EFL, which is a characteristic feature in patients 
with moderate-to-severe COPD with dynamic hyperinflation 
and the loss of lung elastic recoil.17 Previous studies reported 
that EFL is associated with certain symptoms, especially 
dyspnea, and with exacerbations of COPD.26,27 In the present 
study, it was shown that ΔX5 was reduced more in Exacerba-
tors than in Nonexacerbators, among all patients and among 
those with stage II COPD, but without statistical differences. 
Thus, the presence of EFL may not be associated with the 
ability of FOT to discriminate between Exacerbators and 
Nonexacerbators in patients with stage II COPD. Xrs is 
supposed to reflect the compliance and inertial properties of 
the respiratory system; changes in Xrs in pulmonary disease 
are dominated by respiratory compliance but not inertial 
properties.28 Compliance is primarily associated with the 
lung periphery. A study conducted by Borrill et al showed 
that changes in X5 and Fres induced by the administration 
of bronchodilators were related to small airway bronchodi-
lation, causing a reduction in hyperinflation and improve-
ment in lung compliance.29 Therefore, slight perturbations 
of the small airways might have resulted in differences in 
Xrs between Exacerbators and Nonexacerbators in patients 
with stage II COPD, despite no significant differences in 
respiratory function as measured by spirometry. However, 
the reason why FOT discriminated between Exacerba-
tors and Nonexacerbators in this study has not fully been 
elucidated.
In the present study, Xrs values became more negative in 
patients with higher GOLD staging. This is consistent with 
a previous study conducted by Di Mango et al.30 They also 
reported that Xrs was useful in assessing airway obstruction 
in patients with more advanced COPD. Our study did not 
show any clinical utility of FOT in discriminating between 
Exacerbators and Nonexacerbators in patients with severe 
COPD. In this study, ROC curve analysis showed that AUC 
values were higher in Xrs, particularly X5 and Fres, than 
in Rrs, indicating that Xrs is more closely associated with 
exacerbation-prone phenotype of COPD than Rrs. In accor-
dance with our results, Stevenson et al reported that there 
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Figure 2 ROC curve of spirometry and FOT parameters for identification of exacerbations in 119 patients with COPD.
Notes: rOC curve of % predicted FVC (A), % predicted FeV1 (B), FeV1/FVC (C), r5 (D), r20 (E), r5–r20 (F), X5 (G), Fres (H), and alX (I) with the presence of 
exacerbation are shown. high aUC of all parameters of FOT to identify exacerbations were observed.
Abbreviations: alX, reactance area; aUC, area under the curve; FeV1, forced expiratory volume in 1 second; FOT, forced oscillation technique; Fres, resonant frequency; 
FVC, forced vital capacity; rOC, receiver operating characteristic; r5, resistance at 5 hz; r20, resistance at 20 hz; r5–r20, differences between r5 and r20; ΔX5, difference 
between inspiratory and expiratory respiratory system reactance; X5, reactance at 5 hz.
was a significant improvement in X5 but not in R5 during 
recovery from exacerbation of COPD.31 In addition, previous 
studies showed that Xrs was more effective than Rrs in the 
assessment of degree of airflow limitation and air trapping 
in patients with COPD.13,32
Previous studies showed significant correlations between 
FOT parameters and respiratory function as measured by 
spirometry in patients with geriatric COPD.13,32 Therefore, 
FOT, rather than spirometry, can be used to assess airway 
obstruction in patients who have difficulty with forced expi-
ration. FOT is a useful tool in diagnosing COPD, evaluat-
ing disease severity, formulating prognosis, and evaluating 
response to therapy, similar to spirometry. Amaral et al 
recently introduced automatic classifiers to simplify the 
clinical use and increase the accuracy of FOT in the catego-
rization of airway obstruction level in patients with COPD.33 
Such new devices may enable clinicians to categorize COPD 
airway obstruction, track disease progression, evaluate the 
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risk of future disease exacerbations, and guide therapy 
more easily.
Our study has some limitations. First, we could not 
exclude the influence of patients with asthma–COPD over-
lap (ACO), although patients who had evident asthmatic 
components, such as airway hyper-responsiveness, were 
excluded. Studies have shown that patients with ACO have 
more frequent exacerbations than those with COPD only.34,35 
However, at present, there is no definition or basis for exclud-
ing a patient with ACO. Second, we found no difference in 
respiratory impedance between Exacerbators and Nonexacer-
bators among patients with stage III and IV COPD. Although 
it cannot be concluded whether FOT can discriminate an 
exacerbation-prone phenotype among patients with severe 
COPD, it may be superior in discriminating an exacerbation-
prone phenotype in patients with nonsevere COPD compared 
to those with severe COPD. Third, this was a single-centered 
retrospective study and the sample size was relatively small. 
Therefore, we cannot conclude whether FOT parameters can 
predict exacerbations of COPD in clinical practice, particu-
larly in patients with moderate COPD. For this confirmation, 
prospective studies including a greater number of subjects 
are necessary to verify our results.
Conclusion
We found significant differences in FOT parameters between 
Exacerbators and Nonexacerbators, despite no significant 
differences in respiratory function as measured by spirometry 
among patients with stage II COPD. FOT can aid therapeutic 
intervention aimed at the avoidance of COPD exacerbation. 
Prospective studies are required to further explore the utility 
of FOT, such as its superiority to spirometry, in patients 
with COPD.
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association between FOT and exacerbations of COPD
Table S1 Comparisons of parameters measured by spirometry and FOT between the global Initiative for Chronic Obstructive lung 
Disease stages
Parameters Stage I (n=34) Stage II (n=45) Stage III + IV (n=31) P-value
spirometry
% predicted FVC 110.1 (98.9, 115.7) 93.0 (85.4, 107.5) 77.5 (66.7, 95.2) ,0.001*
% predicted FeV1 89.1 (84.3, 94.2) 65.1 (58.1, 70.7) 36.1 (27.9, 43.3) ,0.001*
FeV1/FVC, % 68.1 (62.7, 75.8) 54.9 (45.5, 64.6) 36.5 (31.4, 42.0) ,0.001*
FOT/resistance (r)
r5, kPa⋅l-1⋅s-1 2.86 (2.00, 3.64) 3.37 (2.68, 4.14) 4.19 (3.75, 4.86) ,0.001*
r20, kPa⋅l-1⋅s-1 2.02 (1.50, 2.48) 2.52 (2.08, 3.12) 3.17 (2.68, 3.75) ,0.001*
r5–r20, kPa⋅l-1⋅s-1 0.57 (0.36, 1.08) 0.75 (0.49, 1.30) 1.18 (0.85, 1.59) 0.003*
FOT/reactance (X)
X5, kPa⋅l-1⋅s-1 -0.37 (-0.71, -0.16) -0.87 (-1.75, -0.40) -2.74 (-4.43, -1.89) ,0.001*
Fres, hz 7.21 (5.84, 10.58) 10.32 (7.66, 14.44) 19.71 (15.57, 21.39) ,0.001*
alX, kPa⋅l-1 1.28 (0.61, 4.72) 4.02 (1.48, 12.41) 22.32 (13.26, 35.20) ,0.001*
ΔX5, kPa⋅l-1⋅s-1 -0.07 (-0.34, 0.23) -0.10 (-0.90, 0.18) -1.92 (-4.04, -0.53) ,0.001*
Notes: all values are median (interquartile range) unless otherwise stated. P-values represent comparisons between three groups. The analyses of FOT parameters are 
adjusted for age, gender, height, and smoking status. *P,0.05.
Abbreviations: FOT, forced oscillation technique; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; r5, resistance at 5 hz; r20, resistance at 
20 hz; r5–r20, difference between r5 and r20; X5, reactance at 5 hz; Fres, resonant frequency; alX, reactance area; ΔX5, difference between inspiratory and expiratory 
respiratory system reactance.
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